VIVUS (NASDAQ:VVUS) Cut to Sell at ValuEngine

VIVUS (NASDAQ:VVUS) was downgraded by equities researchers at ValuEngine from a “hold” rating to a “sell” rating in a report released on Monday, ValuEngine reports.

VVUS traded down $0.04 on Monday, hitting $4.22. The company had a trading volume of 171,589 shares, compared to its average volume of 98,576. The stock has a fifty day moving average price of $4.01 and a 200-day moving average price of $3.73. VIVUS has a 12-month low of $2.15 and a 12-month high of $5.78. The stock has a market capitalization of $44.37 million, a price-to-earnings ratio of -1.21 and a beta of 1.78.

VIVUS (NASDAQ:VVUS) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.44. The company had revenue of $18.39 million during the quarter, compared to analysts’ expectations of $16.88 million. On average, research analysts forecast that VIVUS will post -2.44 earnings per share for the current fiscal year.

A hedge fund recently raised its stake in VIVUS stock. BlackRock Inc. raised its stake in VIVUS, Inc. (NASDAQ:VVUS) by 6.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 220,707 shares of the biopharmaceutical company’s stock after purchasing an additional 13,572 shares during the period. BlackRock Inc. owned 2.07% of VIVUS worth $843,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 14.78% of the stock is owned by institutional investors.


VIVUS, Inc operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol.

Read More: Roth IRA

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with's FREE daily email newsletter.